Quick Answer
Hinge Health, Inc. reported R&D Expense of $368.14 million for fiscal year 2025.
Hinge Health, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $368.14M | +265.1% |
| 2024 | $100.84M | -8.4% |
| 2023 | $110.06M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $31.92M | +34.2% | -88.6% |
| June 30, 2025 | $279.96M | +1023.4% | +1077.1% |
| September 30, 2024 | $23.79M | — | -4.6% |
| June 30, 2024 | $24.92M | — | — |
- Hinge Health, Inc. showed an increase of +265.1% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Hinge Health, Inc.’s r&d expense has grown by 234.5% (from $110.06 million to $368.14 million).
- The most recent figure is from Hinge Health, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: